
News|Videos|July 11, 2024
De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis
Multiple sclerosis (MS) treatment specialists discuss the challenges associated with the early use of high-efficacy therapy (HET) in patients with mild to moderate MS and delve into the broader debate surrounding the consistent use of HET for managing mild to moderate MS cases.
Advertisement
Episodes in this series

Are there any challenges associated with early use of HET in patients with mild to moderate MS?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease
2
FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy
3
Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials
4
Advancing DM1 and DMD Care: Insights on DYNE-101 and DYNE-251 Development
5
































